Elanco Animal Health (NYSE:ELAN) Rating Lowered to Hold at Zacks Research

Key Points

• Elanco Animal Health has been downgraded from a "strong-buy" to a "hold" rating by Zacks Research, indicating a shift in analyst sentiment.
• Despite the downgrade, other analysts have varied opinions, with Piper Sandler raising the target price from $12.00 to $18.00 and assigning a "neutral" rating.
• Elanco reported a quarterly EPS of $0.26, exceeding the consensus estimate and showing a 4.8% increase in revenue compared to the previous year.

Elanco Animal Health (NYSE:ELAN - Get Free Report) was downgraded by stock analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Other analysts have also issued research reports about the stock. Piper Sandler upped their target price on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, August 11th. Leerink Partnrs raised shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 17th. Stifel Nicolaus boosted their target price on Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a research note on Wednesday, July 2nd. Wall Street Zen raised Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Finally, UBS Group lifted their price target on Elanco Animal Health from $18.00 to $19.00 and gave the stock a "buy" rating in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $17.33.

Elanco Animal Health Price Performance

ELAN stock opened at $17.5050 on Wednesday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60. The business has a 50-day simple moving average of $15.00 and a two-hundred day simple moving average of $12.42. The company has a market capitalization of $8.70 billion, a P/E ratio of 20.35, a price-to-earnings-growth ratio of 3.24 and a beta of 1.66. Elanco Animal Health has a 52-week low of $8.02 and a 52-week high of $18.08.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.20 by $0.06. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The company's quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Research analysts expect that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Hedge Funds Weigh In On Elanco Animal Health

Several institutional investors have recently bought and sold shares of ELAN. Nuveen LLC purchased a new position in shares of Elanco Animal Health during the 1st quarter valued at $115,212,000. Dimensional Fund Advisors LP boosted its holdings in Elanco Animal Health by 14.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company's stock worth $214,875,000 after buying an additional 2,563,740 shares during the period. Jennison Associates LLC grew its stake in Elanco Animal Health by 322.0% in the 2nd quarter. Jennison Associates LLC now owns 3,234,717 shares of the company's stock valued at $46,192,000 after buying an additional 2,468,122 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock valued at $50,268,000 after acquiring an additional 2,445,872 shares during the period. Finally, ASR Vermogensbeheer N.V. purchased a new stake in shares of Elanco Animal Health during the first quarter worth $23,744,000. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.